Stock data
Viridian Therapeutics, Inc. (VRDN)
Viridian Therapeutics, Inc. (VRDN) reported net income of -US$342.60M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$363.39M | -US$342.60M | — |
| 2024 | — | — | -US$299.04M | -US$269.95M | — |
| 2023 | — | — | -US$254.45M | -US$237.73M | — |
| 2022 | — | — | -US$134.30M | -US$129.87M | — |
| 2021 | — | — | -US$79.73M | -US$79.41M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$127.12M | — |
| 2026-03-31 | — | -US$104.90M | — |
| 2025-12-31 | — | -US$120.36M | — |
| 2025-09-30 | — | -US$34.60M | — |
| 2025-06-30 | — | -US$100.73M | — |
| 2025-03-31 | — | -US$86.91M | — |
| 2024-12-31 | — | -US$79.72M | — |
| 2024-09-30 | — | -US$76.69M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.